26.15

3.03% 0.77

After Hours: 26.09 -0.06 -0.23%

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $26.15, with a volume of 20.62M. It is up +3.03% in the last 24 hours and down -0.68% over the past month. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Previous Close:

$25.38

Open:

$25.55

24h Volume:

20.62M

Relative Volume:

0.62

Market Cap:

$6.05B

Revenue:

$2.35B

Net Income/Loss:

$128.37M

P/E Ratio:

50.09

EPS:

0.5221

Net Cash Flow:

$57.42M

1W Performance:

+10.11%

1M Performance:

-0.68%

6M Performance:

-34.23%

1Y Performance:

-50.10%

1-Day Range:

$24.13

$26.64

1-Week Range:

$23.36

$26.64

52-Week Range:

$13.74

$70.43

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

2,442

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	26.15	5.87B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	15.96	51.03B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	35.32	40.20B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.06	40.78B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	77.69	32.81B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	556.82	23.86B	3.17B	1.29B	1.01B	27.09

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	JP Morgan	Overweight
Mar-10-26	Upgrade	BofA Securities	Underperform → Neutral
Mar-10-26	Upgrade	Citigroup	Sell → Neutral
Mar-09-26	Upgrade	Needham	Hold → Buy
Feb-24-26	Downgrade	BTIG Research	Buy → Neutral
Jan-12-26	Initiated	Evercore ISI	In-line
Dec-09-25	Initiated	Barclays	Overweight
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy
Apr-29-25	Downgrade	TD Cowen	Buy → Hold
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

May 29, 2026

Telehealth Co. Hims Likely To Get Suicide Suit Trimmed - Law360

May 29, 2026

Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot - Barron's

May 29, 2026

Hims & Hers Health Options Spot-On: On May 29th, 229.43K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo

May 29, 2026

Hims & Hers Expands Integrated Health Access via Platform Expansion - The Globe and Mail

May 29, 2026

Hims And Hers Canadian GLP 1 Push Tests Broader Wellness Subscription Thesis - Yahoo Finance

May 29, 2026

$Hims & Hers Health (HIMS.US)$ keep her going🤑📈 - Moomoo

May 29, 2026

Flo Health Expands Distribution Through Collaboration With Hims & Hers Benefits - TipRanks

May 29, 2026

May 28, 2026

HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - TradingView

May 28, 2026

Hims & Hers adds eight partners to subscriber benefits program By Investing.com - Investing.com Australia

May 28, 2026

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey

May 28, 2026

Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners - Business Wire

May 28, 2026

HIMS Stock Heads For Weekly Loss — But Ex-Netflix CFO Is Buying The Dip Despite BofA’s GLP-1 Warning - Stocktwits

May 28, 2026

Hims & Hers Health Expands Benefits Program With Eight New Partners - TradingView

May 28, 2026

One Subscription. Ten Ways to Feel Your Best. - Hims & Hers Newsroom

May 28, 2026

Hims & Hers Debt-Funded Expansion Tests Its Global Telehealth Ambitions - Investing.com

May 28, 2026

Hims & Hers eyes global growth: Will $1.15B Eucalyptus deal fuel its recovery or dilute shareholders? - MSN

May 28, 2026

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? - MarketBeat

May 28, 2026

HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN

May 28, 2026

May 27, 2026